Get started
ProQR Therapeutics N.V.ProQR Therapeutics N.V.ProQR Therapeutics N.V.

ProQR Therapeutics N.V.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Options

PRQR chart


Full chart

PRQR upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪150.45 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.35 USD
Net income (FY)
‪−30.03 M‬ USD
Revenue (FY)
‪20.45 M‬ USD
Shares float
‪70.76 M‬
Beta (1Y)
1.85

Employees


Employees (FY)
166
Change (1Y)
+10 +6.41%
Revenue / Employee (1Y)
‪123.11 K‬ USD
Net income / Employee (1Y)
‪−180.80 K‬ USD

About ProQR Therapeutics N.V.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Daniel Anton de Boer
Website
proqr-tx.com
Headquarters
Leiden
Founded
2012
ISIN
NL0010872495
FIGI
BBG006N8B830
ProQR Therapeutics NV is a clinical stage biopharmaceutical company, which engages in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases with a focus on inherited retinal diseases. The company was founded by Daniel Anton de Boer, Gerard J. Platenburg, Henri A. Termeer, and Domenico Valerio on February 21, 2012, and is headquartered in Leiden, the Netherlands.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

PRQR news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as PRQR.

Frequently Asked Questions


The current price of PRQR is 1.54 USD — it has increased by 7.69% in the past 24 hours. Watch ProQR Therapeutics N.V. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange ProQR Therapeutics N.V. stocks are traded under the ticker PRQR.
PRQR stock has risen by 37.50% compared to the previous week, the month change is a 5.48% rise, over the last year ProQR Therapeutics N.V. has showed a −21.03% decrease.
We've gathered analysts' opinions on ProQR Therapeutics N.V. future price: according to them, PRQR price has a max estimate of 15.70 USD and a min estimate of 4.18 USD. Watch PRQR chart and read a more detailed ProQR Therapeutics N.V. stock forecast: see what analysts think of ProQR Therapeutics N.V. and suggest that you do with its stocks.
PRQR reached its all-time high on Mar 16, 2015 with the price of 27.60 USD, and its all-time low was 0.53 USD and was reached on May 11, 2022. View more price dynamics on PRQR chart.
See other stocks reaching their highest and lowest prices.
PRQR stock is 8.77% volatile and has beta coefficient of 1.85. Track ProQR Therapeutics N.V. stock price on the chart and check out the list of the most volatile stocks — is ProQR Therapeutics N.V. there?
Today ProQR Therapeutics N.V. has the market capitalization of ‪162.03 M‬, it has increased by 1.79% over the last week.
Yes, you can track ProQR Therapeutics N.V. financials in yearly and quarterly reports right on TradingView.
ProQR Therapeutics N.V. is going to release the next earnings report on May 8, 2025. Keep track of upcoming events with our Earnings Calendar.
PRQR earnings for the last quarter are −0.093 USD per share, whereas the estimation was −0.096 USD resulting in a 2.94% surprise. The estimated earnings for the next quarter are −0.10 USD per share. See more details about ProQR Therapeutics N.V. earnings.
ProQR Therapeutics N.V. revenue for the last quarter amounts to ‪4.46 M‬ USD, despite the estimated figure of ‪5.17 M‬ USD. In the next quarter, revenue is expected to reach ‪5.71 M‬ USD.
PRQR net income for the last quarter is ‪−9.93 M‬ USD, while the quarter before that showed ‪−8.91 M‬ USD of net income which accounts for −11.44% change. Track more ProQR Therapeutics N.V. financial stats to get the full picture.
No, PRQR doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 29, 2025, the company has 166 employees. See our rating of the largest employees — is ProQR Therapeutics N.V. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ProQR Therapeutics N.V. EBITDA is ‪−30.67 M‬ USD, and current EBITDA margin is −149.97%. See more stats in ProQR Therapeutics N.V. financial statements.
Like other stocks, PRQR shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ProQR Therapeutics N.V. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ProQR Therapeutics N.V. technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ProQR Therapeutics N.V. stock shows the sell signal. See more of ProQR Therapeutics N.V. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.